for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Basilea To Progress With Lisavanbulin To Phase 2 Study

Dec 16 (Reuters) - BASILEA PHARMACEUTICA AG:

* BASILEA PLANS PROGRESSION OF ONCOLOGY CANDIDATE LISAVANBULIN TO TARGETED, BIOMARKER-DRIVEN PHASE 2 STUDY

* BASILEA PHARMACEUTICA AG - CONFIRMED SIGNALS OF EFFICACY WITH PROFOUND RESPONSES IN TWO PATIENTS WITH GLIOBLASTOMA ACROSS TWO DIFFERENT CLINICAL STUDIES

* BASILEA PHARMACEUTICA AG - PLAN TO PROCEED WITH TARGETED, BIOMARKER-DRIVEN ORAL EXPANSION STUDY IN MID-2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up